Bortezomib in the treatment of multiple myeloma

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promisin...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Springer eBooks.
Autor Corporativo:	SpringerLink (Online service)
Outros Autores:	Ghobrial, Irene M., Richardson, Paul G., Anderson, Kenneth C.
Formato:	Electronic Resource
Idioma:	English
Publicado em:	Basel Springer Basel c2011.
Assuntos:	Multiple myeloma > Treatment. Multiple myeloma > Chemotherapy. Antineoplastic agents. Boronic Acids > Therapeutic use. Multiple myeloma > Drug therapy. Antineoplastic agents > Therapeutic use. Protease inhibitors > Therapeutic use. Proteasome endopeptidase complex > Antagonists & inhibitors. Pyrazines > Therapeutic use. Electronic books.
Acesso em linha:	Available for University of the Philippines Diliman via SpringerLink. Click here to access